Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
COEGIN PHARMA Aktie jetzt für 0€ handeln | |||||
12.02. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 12.02.2025 | 515 | Xetra Newsboard | The following instruments on XETRA do have their first trading 12.02.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 12.02.2025
Aktien
1 JP3556000002 Toa Corp.
2 CNE100006NX7... ► Artikel lesen | |
06.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 06.01.2025 | 524 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 06.01.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 06.01.2025ISIN NameSE0020357754 COEGIN PHARMA ABDE000DJ9AB57... ► Artikel lesen | |
25.11.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.11.2024 | 1.774 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.11.2024
Aktien
1 ID1000113707 PT Bank Tabungan Negara... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 16,900 | -1,74 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 40,170 | -0,05 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
BEAM THERAPEUTICS | 18,760 | +15,02 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
NUVALENT | 79,54 | +3,43 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 29,250 | +1,35 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
CG ONCOLOGY | 28,670 | +4,41 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,880 | -2,03 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
AVIDITY BIOSCIENCES | 47,615 | +0,82 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
IMMUNOVANT | 16,700 | +10,82 % | Immunovant reports promising remission data for Graves' disease therapy | ||
KALARIS THERAPEUTICS | 4,570 | +14,25 % | Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates | Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular... ► Artikel lesen | |
EVOTEC | 5,860 | +1,21 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
HARMONY BIOSCIENCES | 37,550 | +1,24 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,630 | -0,64 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
89BIO | 9,240 | +0,49 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,530 | -1,30 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress |